

Marcus D SÃœemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8289999/publications.pdf>

Version: 2024-02-01

38
papers

1,223
citations

471509

17
h-index

377865

34
g-index

39
all docs

39
docs citations

39
times ranked

2371
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>PLoS Medicine</i> , 2014, 11, e1001750.	8.4	184
2	Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2005, 115, 468-475.	8.2	131
3	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. <i>European Heart Journal</i> , 2015, 36, ehv352.	2.2	116
4	Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. <i>American Journal of Transplantation</i> , 2019, 19, 907-919.	4.7	82
5	The versatility of HDL: a crucial anti-inflammatory regulator. <i>European Journal of Clinical Investigation</i> , 2010, 40, 1131-1143.	3.4	77
6	Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status. <i>BMC Nephrology</i> , 2013, 14, 266.	1.8	77
7	Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. <i>Scientific Reports</i> , 2016, 6, 33678.	3.3	70
8	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. <i>Clinical Chemistry</i> , 2018, 64, 597-608.	3.2	52
9	Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna Investigation of Atrial Fibrillation and Thromboembolism in Patients on Hemodialysis (VIVALDI). <i>PLoS ONE</i> , 2017, 12, e0169400.	2.5	51
10	Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Immunoadsorption. <i>PLoS ONE</i> , 2014, 9, e103568.	2.5	43
11	Molecular regulation of the renin-angiotensin system in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 115-123.	0.7	34
12	Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial. <i>BMC Nephrology</i> , 2017, 18, 238.	1.8	33
13	Fluid status and outcome in patients with heart failure and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2017, 230, 476-481.	1.7	26
14	Bioimpedance Spectroscopy for Assessment of Volume Status in Patients before and after General Anaesthesia. <i>PLoS ONE</i> , 2014, 9, e111139.	2.5	25
15	Diabetes-related end-stage renal disease in Austria 1965-2013. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1920-1927.	0.7	25
16	Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 614-617.	0.9	24
17	Critical Role of Neprilysin in Kidney Angiotensin Metabolism. <i>Circulation Research</i> , 2020, 127, 593-606.	4.5	23
18	Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. <i>Annals of Medicine</i> , 2017, 49, 525-533.	3.8	16

#	ARTICLE	IF	CITATIONS
19	Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 355-365.	0.6	14
20	Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1211-1216.	2.3	13
21	Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis. <i>PLoS ONE</i> , 2017, 12, e0180900.	2.5	12
22	Antidiabetic therapy in post kidney transplantation diabetes mellitus. <i>Transplantation Reviews</i> , 2015, 29, 145-153.	2.9	11
23	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. <i>Transplant International</i> , 2004, 17, 481-489.	1.6	10
24	Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy. <i>Clinical Transplantation</i> , 2015, 29, 1230-1238.	1.6	8
25	Molecular remodeling of the renin-angiotensin system after kidney transplantation. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2017, 18, 147032031770523.	1.7	8
26	Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. <i>Scientific Reports</i> , 2017, 7, 9644.	3.3	8
27	Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. <i>Scientific Reports</i> , 2019, 9, 9762.	3.3	8
28	Uncovering host defences in the urinary tract: cathelicidin and beyond. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 347-349.	0.7	7
29	Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers. <i>BMC Immunology</i> , 2016, 17, 11.	2.2	7
30	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. <i>Transplant International</i> , 2004, 17, 481-489.	1.6	6
31	Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis. <i>Transplant Immunology</i> , 2008, 20, 14-20.	1.2	6
32	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0145319.	2.5	5
33	Sports and HDL-Quality Reflected By Serum Amyloid A and Surfactant Protein B. <i>International Journal of Medical Sciences</i> , 2017, 14, 1040-1048.	2.5	4
34	Response to: Correspondence on "Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors" by Patoulias. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e196-e196.	0.9	2
35	FP274ACE-INDEPENDENT RAS ENZYME ACTIVITIES IN HEART TRANSPLANT PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii158-iii159.	0.7	0
36	MOO2OCHYMASE AND NEPRILYSIN ARE KEY REGULATORS OF THE CLASSICAL AND ALTERNATIVE RENIN ANGIOTENSIN SYSTEM (RAS) AFTER KIDNEY TRANSPLANTATION: IMPLICATIONS FOR RAS BLOCKING THERAPY. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i36-i36.	0.7	0

#	ARTICLE	IF	CITATIONS
37	SP479HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS ON HEMODIALYSIS. Nephrology Dialysis Transplantation, 2016, 31, i253-i253.	0.7	0
38	04.05â€¦The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , .		0